This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): rhuMAb-E25, IGE025, RG3648
Description: Xolair is an anti-immunoglobulin E antibody whose therapeutic effect has been validated through clinical trials in patients suffering from allergic asthma. In June 2002, Xolair received marketing approval in Australia for treating adults and adolescents with moderate allergic asthma. It was approved in the U.S. on June 20, 2003.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Xolair was developed by Genentech, allegedly after Tanox attempted to partner with Genentech to develop anti-IgE monoclonal antibodies. Tanox then partnered with Ciba-Geigy, now Novartis, to developed anti-IgE monoclonal antibodies. Novartis and Genentech agreed to develop Xolair over Tanoxs TNX-901 antibody, paying a royalty to Tanox.
In February 2004, Genentech, Inc., Novartis Pharma AG and Tanox, Inc. settled all litigation pending among them, and finalized the detailed terms of their three-party collaboration, begun in 1996, to govern the development andcommercialization of certain anti-IgE antibodies including Xolair and TNX-901. This arrangementmodifies the arrangement related to Xolair that Genentech entered into with Novartis in 2000. All three parties are co-developing Xolair in the U.S., and Genentech and Novartis are co-promoting Xolair in the U.S. and both will make certain joint and individual payments to...See full deal structure in Biomedtracker
Partners: Novartis AG PDL BioPharma, Inc. DRI Capital Inc.
Additional information available to subscribers only: